Results 101 to 110 of about 53,534 (265)
Interventional oncology in children: Where are we now?
Abstract Paediatric Interventional Oncology (IO) lags behind adult IO due to a scarcity of specific outcome data. The suboptimal way to evolve this field is relying heavily on adult experiences. The distinct tumour types prevalent in children, such as extracranial germ cell tumours, sarcomas, and neuroblastoma, differ strongly from those found in ...
Premal Amrishkumar Patel +1 more
wiley +1 more source
BACKGROUND AND OBJECTIVE: Stent fracture (SF), in peripheral vessels and although in coronary arteries has been reported. Very late and after one year stent thrombosis in drug eluting stent (DES) is a rare phenomenon and its most frequent cause is ...
A Ghaemian,, M Saravi
doaj
Which spring is the best? Comparison of methods for virtual stenting.
This paper presents a methodology for modeling the deployment of implantable devices used in minimally invasive vascular interventions. Motivated by the clinical need to perform preinterventional rehearsals of a stent deployment, we have developed ...
Spranger, K, Ventikos, Y
core
Coronary Stent Thrombosis in Acute Coronary Syndromes
Background: In ACS patients who are treated with a primary percutaneous coronary intervention (pPCI), stent thrombosis is a serious and potentially lethal complication.
Xavier Mueller +11 more
core +1 more source
Imaging of Abdominal Complications in Children With Acute Lymphoblastic Leukaemia
ABSTRACT Acute lymphoblastic leukaemia (ALL) is the most common paediatric malignancy and remains one of the most common causes of cancer‐related death in children and adolescents. Five‐year overall survival rates now exceed 90% with current multidrug chemotherapeutic regimens. This improvement, coupled with the toxicity of chemotherapy, has led to the
Luke R. Holmes +2 more
wiley +1 more source
Summary Introduction Patients who require major vascular surgery often receive antiplatelet therapy for primary or secondary prevention of cardiovascular disease. Clopidogrel resistance and variability in platelet recovery after drug discontinuation pose clinical challenges, particularly for regional anaesthesia and blood management.
Akshay Shah +11 more
wiley +1 more source
SYNERGY Early Stent Thrombosis
SYNERGY (Boston Scientific, Marlborough, Massachusetts), the first metallic bioresorbable polymer drug-eluting stent (DES) approved by the U.S. Food and Drug Administration, incorporates design elements intended to expedite stent healing and enhance safety [(1)][1].
Dean J, Kereiakes, Juan F, Granada
openaire +2 more sources
Introduction Lower extremity deep venous thrombosis (DVT) with severe iliac vein stenosis is common and can lead to significant morbidity and mortality.
Shuaishuai Mao +3 more
core +1 more source
Stent thrombosis remains a severe complication after deployment owing to its high mortality. In the current report, we present a case of stent thrombosis distal to the segment showing flow-limiting early in-stent restenosis with an everolimus-eluting ...
Ishibashi, Ken +5 more
core +1 more source
ABSTRACT Background The data elements and indicators in a clinical quality registry (CQR) contribute towards the utility of its output and should be informed by stakeholder input. In Australia and Aotearoa New Zealand (AANZ), there is no CQR for pancreatic cancer surgery. This study aimed to select data elements and registry aims with stakeholder input.
Elizabeth Lockie +40 more
wiley +1 more source

